National Academy of Inventors Names Miller School of Medicine’s Dr. Sylvia Daunert Fellow for Lifetime of Innovation
“Without imagination, you don’t go anywhere in life.”
It is a lesson Sylvia Daunert, Ph.D., Lucille P. Markey Chair in Biochemistry and Molecular Biology and director of the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (BioNIUM), first heard from her father as a child. Decades later, that advice continues to guide a scientific career defined by innovation, creativity and a determination to solve some of medicine’s most pressing challenges.
Dr. Daunert has been recognized with one of the highest honors bestowed upon inventors with her election as a Fellow of the National Academy of Inventors (NAI). The distinction recognizes academic inventors whose patented discoveries have demonstrated meaningful impact on society through innovation, commercialization and technology transfer.
“It has always been my dream to design things and come up with ways to help humankind,” Dr. Daunert said. “Being recognized by the National Academy of Inventors means a great deal to me because creativity and invention are such an important part of who I am.”
Dr. Daunert’s career spans biosensors, nanotechnology, drug delivery systems, imaging technologies and translational medicine. She is named as an inventor on more than 50 U.S. patents, along with numerous international patents. Several of those technologies have been licensed to industry partners or incorporated into commercial research and development pipelines.
Her passion for innovation may have deeper roots than she once realized. While researching patents, Dr. Daunert discovered that her great-great-grandfather held patents related to battery technology in Germany.
“I guess I come from a long line of engineers,” she said.
A Promising New Approach to Brain Injury Treatment
Dr. Daunert points to a recent breakthrough in nanomedicine as an example of the translational impact she hopes scientific innovation can achieve.
Working with researchers from The Miami Project to Cure Paralysis, Dr. Daunert helped develop a patented nanodrug platform designed to rapidly cool the brain following traumatic brain injury. The technology uses nanoparticles created from vanilloid compounds and is administered through the nose, allowing therapeutic agents to reach the brain quickly and directly.
The work addresses a longstanding challenge in emergency medicine. Therapeutic hypothermia, or controlled cooling, has shown promise in protecting vulnerable brain tissue after traumatic injury, stroke and cardiac arrest. Existing approaches typically require cooling the entire body using specialized hospital equipment, often after valuable time has been lost.
Dr. Daunert’s team took a different approach.
Researchers engineered “nanovanilloids” from compounds that activate TRPV1 receptors involved in body-temperature regulation. Because the nanoparticles are delivered intranasally, they can bypass many of the body’s natural barriers and rapidly reach the brain. In preclinical studies, the treatment reduced brain temperature by 2.0 to 3.6 degrees Celsius for up to three hours while avoiding the need to cool the rest of the body.
According to Dr. Daunert, the ultimate goal is to move neuroprotective treatment closer to the point of injury.
“We envision a future in which first responders can administer treatment immediately after a traumatic brain injury, helping protect vulnerable neurons before a patient even reaches the hospital,” Dr. Daunert said.
The potential applications extend far beyond traumatic brain injury. Dr. Daunert said the technology could eventually be used for stroke, cardiac arrest and military battlefield injuries, where every minute can affect long-term outcomes. By cooling the brain rapidly through a nasal spray rather than relying on hospital-based cooling methods, clinicians may be able to reduce irreversible neurological damage before it occurs.
“This technology reflects our commitment to translating fundamental discoveries into practical solutions that have the potential to improve patient care and save lives,” Dr. Daunert said.
Innovation Inspired by Possibility
For Dr. Daunert, successful invention requires equal parts imagination and perseverance.
“I don’t want to hear that something can’t be done,” she said. “There is always a solution to a problem.”
That philosophy has earned recognition from prestigious scientific organizations around the world. In addition to her election to the National Academy of Inventors, Dr. Daunert is a member of the Royal Society of Chemistry, the Royal Academy of Pharmacy of Catalonia and the Bologna Academy, among other distinguished organizations.
“Innovation begins with imagination,” Dr. Daunert said. “When you allow yourself to think beyond what exists today, you create opportunities to solve tomorrow’s challenges.”
For the scientist whose father taught her that imagination opens doors, election to the National Academy of Inventors represents recognition of a lifelong commitment to creating discoveries that improve lives and a reminder that some of the most transformative ideas begin by asking what might be possible.
More from the Miller School of Medicine
University of Miami’s 3D bioprinting facility is creating living tissues and patient-specific implants to transform patient care.
The Miller School team developed a nanodrug platform for targeted therapeutic hypothermia after traumatic brain injury.
Miller School researchers found that arbon disulfide could serve as an early biomarker for ventilator-associated pneumonia.
Miller School and V.A. researchers will tease out the virus’s relationship with cardiac low-density lipoprotein (LDL) receptors.
Tags: biochemistry and molecular biology, BioNIUM, Department of Biochemistry and Molecular Biology, Dr. Sylvia Daunert, technobiology, technology